The estimated Net Worth of John Richard Sylvester is at least $105 mil dollars as of 21 August 2023. Mr. Sylvester owns over 10,550 units of Delcath Systems stock worth over $105,078 and over the last 4 years he sold DCTH stock worth over $0. In addition, he makes $0 as Independent Director at Delcath Systems.
John has made over 1 trades of the Delcath Systems stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 10,550 units of DCTH stock worth $50,640 on 21 August 2023.
The largest trade he's ever made was buying 10,550 units of Delcath Systems stock on 21 August 2023 worth over $50,640. On average, John trades about 1,758 units every 0 days since 2020. As of 21 August 2023 he still owns at least 10,550 units of Delcath Systems stock.
You can see the complete history of Mr. Sylvester stock trades at the bottom of the page.
John Richard Sylvester serves as Independent Director of the Company. He is currently serving as CEO of Curium Pharma’s SPECT and International businesses. Prior to that he served as Chief Commercial Officer of BTG plc, which he joined in 2011 and had roles leading both their Interventional Oncology and Interventional Vascular businesses as well as a period as Chief Development Officer accountable for Strategy, M&A and Market access. This culminated in an exit to Boston Scientific for $4.2 billion. Prior to BTG, John was Managing Director of Biocompatibles plc, building their Interventional Oncology business which led to a successful exit to BTG for £166.0 million. John joined Biocompatibles following a period as the Vice President of Marketing for Baxter Healthcare’s $750.0 million European Medication Delivery business based in Brussels then Zurich accountable for six strategic business units incorporating drugs, devices and drug device combinations. Before this, John held a number of senior commercial roles in the industrial sector. Immediately prior to Baxter Healthcare, John was the General Manager of a Minerals company with $4.0 billion of assets on three continents, $500.0 million of sales and 1,500 employees. John graduated with joint honours in Biochemistry and Applied Molecular Biology from the University of Manchester Institute of Science and Technology (U.M.I.S.T.).
John Sylvester is 56, he's been the Independent Director of Delcath Systems since 2019. There are 6 older and 3 younger executives at Delcath Systems. The oldest executive at Delcath Systems, Inc. is Roger Stoll, 78, who is the Non-Executive Independent Chairman of the Board.
John's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC., 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804.
Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel y Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Delcath Systems executives and other stock owners filed with the SEC include: